Physician profile
Everett Grahn
NPI 1477593770
$8,978.23
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,750 · 2020: $1,279 · 2021: $346 · 2022: $365 · 2023: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $851.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $781.22 | 2019-2021 | |
| Eisai INC. | $758.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $703.99 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $603.53 | 2019-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $594.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $559.44 | 2019-2023 | |
| Amgen INC. | $499.56 | 2019-2020 | |
| Seagen INC. | $317.61 | 2019-2023 | Tukysa |
| Exelixis INC. | $305.93 | 2019 | |
| Janssen Biotech, INC. | $304.33 | 2019-2020 | |
| Genzyme Corporation | $285.91 | 2019-2020 | |
| Pfizer INC. | $251.68 | 2019-2020 | |
| Abbvie INC. | $191.94 | 2019-2022 | |
| Puma Biotechnology, INC. | $173.94 | 2019 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everett Grahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.